New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
08:06 EDTTEVA, ACTITeva's laquinimod for multiple sclerosis shows positive Phase 3 results
Teva and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study that assessed the progression of disability and safety of oral laquinimod in early versus delayed-start relapsing-remitting multiple sclerosis patients. The study compared the effectiveness of laquinimod in patients who received 36 months (early-start) versus those who received 24 months of laquinimod treatment (delayed-start). Laquinimod is an oral, once daily, investigational drug in Phase III studies for RRMS. Overall, early start patients were less likely to experience disease progression than those with a delayed start of Laquinimod (11.8% risk of confirmed disability progression vs 16.7%). The study also supports a favorable safety and tolerability profile of laquinimod in RRMS patients. No new safety concerns arose during the open-label phase. Additionally, data suggests laquinimod has potential restorative and anti-inflammatory properties.
News For TEVA;ACTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
10:00 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:46 EDTTEVAMylan buyout below $95/share favorable for Teva, says Leerink
Subscribe for More Information
07:43 EDTTEVABernstein specialty pharmaceutical analyst has analyst/industry conference call
Subscribe for More Information
06:30 EDTTEVATeva initiated with a Buy at BTIG
Subscribe for More Information
July 6, 2015
13:44 EDTTEVAMylan calls active after report of new Teva bid
Subscribe for More Information
12:31 EDTTEVATeva to bump bid for Mylan up to $86-$88 per share, Bloomberg says
Teva (TEVA) plans to raise its takeover bid for Mylan (MYL) to $86 to $88 per share from the $82 per share it offered in April, reported Bloomberg, citing people with knowledge of the matter, who said the sweetened bid could be announced as soon as this week. Shares of Mylan are up 0.8% to $70.69 following the report, while Teva shares are up 0.3% to $61.74. Reference Link
12:22 EDTTEVAMylan jumps after Bloomberg report of new Teva bid
Subscribe for More Information
12:18 EDTTEVATeva planning to raise Mylan bid to $86-$88/share, Bloomberg reports
Subscribe for More Information
July 1, 2015
08:30 EDTTEVATeva launches generic Aggrenox capsules in the U.S.
Teva announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Aggrenox capsules had annual sales of approximately $457M in the United States, according to IMS data as of April.
08:11 EDTTEVATeva, Xenon provide update on TV-45070 Phase 2b study in OA pain
Subscribe for More Information
08:04 EDTTEVATeva, Xenon Pharmaceuticals provide update on TV-45070 Phase 2b study
Subscribe for More Information
08:01 EDTTEVATeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
08:27 EDTTEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
June 26, 2015
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVAEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVA, ACTITeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
June 23, 2015
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use